The Japanese regulatory authorities have approved Sanwa Kagaku Kenkyusho's Serocion Cap (propagermanium) for the treatment of chronic hepatitis B infection. This orally-active agent is an organic germanium compound and, while it has no direct antiviral activity, it seems to act by stimulating killer T cells and macrophages to produce interleukins and interferons, thereby inhibiting the growth and spread of the virus.
In clinical trials, propagermanium was found to have a clinical efficacy of an order similar to interferon preparations which are already on the market for this indication. However, the company claims the drug is easier to administer, allowing outpatient treatment, and has fewer side effects. Fever symptoms are a common problem with interferons and often limit treatment. The main adverse reactions were skin rash, itchiness, anorexia and gastrointestinal symptoms. The company has also filed for approval to market Serocion for hepatitis C infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze